Maybe this kind of outlier explains why the company isn’t highlighting retatrutide much in their investor updates lately.
Someone in a phase 3 retatrutide study just got unusual bloodwork back. I believe he mentioned being on the top dose. Like the rest of us using it, he’s hoping the medication isn’t responsible. The discussion he posted notes it’s been four weeks since his last shot after being told to stop because of liver-function problems and other blood-count issues.